INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 273 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2023. The put-call ratio across all filers is 0.28 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,474,531 | -23.9% | 85,900 | -7.5% | 0.59% | -0.3% |
| Q2 2023 | $5,882,428 | +105.0% | 92,900 | +75.3% | 0.59% | +38.9% |
| Q1 2023 | $2,869,950 | -54.4% | 53,000 | -55.5% | 0.42% | -53.2% |
| Q4 2022 | $6,297,480 | -17.4% | 119,000 | -27.4% | 0.91% | +40.0% |
| Q3 2022 | $7,627,000 | -46.3% | 163,900 | -34.2% | 0.65% | -59.5% |
| Q2 2022 | $14,213,000 | +10.6% | 249,000 | +18.6% | 1.60% | +47.6% |
| Q1 2022 | $12,850,000 | – | 210,000 | – | 1.08% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TANG CAPITAL MANAGEMENT LLC | 700,000 | $42,833,000 | 8.57% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 308,819 | $18,897,000 | 7.82% |
| Vahanian & Associates Financial Planning Inc. | 45,533 | $2,786,000 | 6.44% |
| DCF Advisers, LLC | 238,500 | $14,594,000 | 6.39% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 50,956 | $20,930,000 | 4.72% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,531,923 | $93,738,000 | 2.86% |
| Nicholas Investment Partners, LP | 562,373 | $34,412,000 | 2.45% |
| Bellevue Group AG | 3,429,619 | $209,859,000 | 2.44% |
| WASATCH ADVISORS LP | 7,477,868 | $457,571,000 | 2.25% |
| Quantum Private Wealth, LLC | 73,772 | $4,514,000 | 1.95% |